Publicaciones en colaboración con investigadores/as de Consorci Sanitari de Terrassa (19)

2024

  1. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes

    Journal of Crohn's and Colitis, Vol. 18, Núm. 3, pp. 349-359

  2. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

  3. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  4. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

2023

  1. Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study

    Cancers, Vol. 15, Núm. 3

  2. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

2022

  1. Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)

    Journal of Clinical Medicine, Vol. 11, Núm. 6

  2. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  3. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  4. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953

2020

  1. Clinical and Pathological Characterization of Lynch-Like Syndrome

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 2, pp. 368-374.e1

  2. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 89-98

  3. Correction to: Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry (Surgical Endoscopy, (2020), 34, 3, (1112-1122), 10.1007/s00464-019-06858-z)

    Surgical Endoscopy

  4. Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry

    Surgical Endoscopy, Vol. 34, Núm. 3, pp. 1112-1122

  5. Retrospective cohort study: Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test

    World Journal of Gastroenterology, Vol. 26, Núm. 1, pp. 70-85

  6. Risk of cancer in family members of patients with lynch-like syndrome

    Cancers, Vol. 12, Núm. 8, pp. 1-12

2017

  1. The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients

    International Journal of Cancer, Vol. 140, Núm. 10, pp. 2201-2211

2016

  1. Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. Effectiveness of adalimumab in perianal fistulas in Crohn's disease patients naive to Anti-TNF therapy

    Journal of Clinical Gastroenterology, Vol. 49, Núm. 1, pp. 34-40